We are live on ! Find out more
GRCE icon

Grace Therapeutics
GRCE

8 hedge funds and large institutions have $784K invested in Grace Therapeutics in 2016 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.28% less ownership

Funds ownership: 3.94% → 3.66% (-0.28%)

33% less funds holding

Funds holding: 12 → 8 (-4)

98% less capital inflows, than outflows

Capital inflows: $1.36K | Capital outflows: $60.2K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
8
Holders Change
-4
Holders Change %
-33.33%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$747
2
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$612

Top Sellers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$37.8K
2
Jane Street
Jane Street
New York
-$16K
3
UBS Group
UBS Group
Switzerland
-$5K
4
Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services
Florida
-$1K
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$340

GRCE Hedge Fund Activity: Q2 2016 in Review

8 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q2 2016, worth a combined $784K — down 14% from $914K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of GRCE and 0 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $747. The largest seller was Bank of Montreal, cutting an estimated $37.8K.

  • 8 institutional investors held Grace Therapeutics (GRCE) as of Q2 2016, down from 12 in Q1 2016.
  • Funds reported $784K of Grace Therapeutics stock for Q2 2016, down 14% quarter-over-quarter.
  • 0 funds opened new Grace Therapeutics positions in Q2 2016 and 4 closed out, a net change of -4 holders.
  • The largest Grace Therapeutics buyer in Q2 2016 was Renaissance Technologies, an estimated $747 added.
  • The largest Grace Therapeutics seller in Q2 2016 was Bank of Montreal, an estimated $37.8K sold.

Based on aggregated 13F filings for Q2 2016.